---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028411"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:46:03.746961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience Q2 FYARRO sales $6.2M (+80% YoY); advancing PRECISION1 and new trials

## Summary
- FYARRO net product sales $6.2M in Q2 2023, up ~6% QoQ and 80% YoY from $3.4M.
- Net loss $18.0M for Q2 2023 (vs $18.3M prior year); cash $134.9M expected to fund into 2025.
- PRECISION1 trial interim analysis on 40 patients with appropriate follow-up expected before end of 2023.
- Phase 2 trials in endometrial cancer (nab-sirolimus + letrozole) and NETs to initiate in Q4 2023.
- First patient dosed in Phase 1/2 KRAS G12C trial with adagrasib (Mirati collaboration).

## SEC filing metadata
- accession: 0001628280-23-028411
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/0001628280-23-028411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/aadi-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028411
- JSON: https://secwatch.observer/filing/0001628280-23-028411.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028411.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported the second quarter of 2023 results: revenue $6.2 million.
  - Period: the second quarter of 2023
  - Revenue: $6.2 million
  - Result: reported results
  source text: Exhibit 99.1 Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/0001628280-23-028411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.